Current and future therapy for pulmonary hypertension in patients with right and left heart failure

References

• Badesch DB, Champion HC, Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54, S55–S66 (2009).
   PubMed Web of Science ®Google Scholar
• Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy control subjects: a systemic review. Eur. Respir. J.34, 888–894 (2009).
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest126, 7S–10S (2004).
   PubMed Web of Science ®Google Scholar
• Fox C, Kalarickal M, Yarborough MJ, Jin J. Perioperative management including new pharmacological vistas for patients with pulmonary hypertension for non-cardiac surgery. Curr. Opin. Anaesthesiol.21, 467–472 (2008).
   PubMed Web of Science ®Google Scholar
• Hurst’s The Heart (12th Edition). Fuster V, Walsh RA, O’Rourke RA, Poole-Wilson P (Eds). McGraw Hill Medical, NY, USA, 1633–1647 (2008).
   Google Scholar
• Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med.107, 216–233 (1987).
   PubMed Web of Science ®Google Scholar
• Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation102, 1718–1723 (2000).
   PubMed Web of Science ®Google Scholar
• Peacock AJ. Primary pulmonary hypertension. Thorax54, 1107–1118 (1999).
   PubMed Web of Science ®Google Scholar
• Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin. Proc.75(6), 625–630 (2000).
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In: Primary Pulmonary Hypertension. Rubin L, Rich S (Eds). Marcel Dekker, NY, USA, 83–129 (1997).
   Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med.327, 76–81 (1992).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension. Eur. Respir. J.12, 265–270 (1998).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Ioos V et al. Who benefits from long-term calcium channel blocker therapy in primary pulmonary hypertension? Am. J. Respir. Crit. Care Med.167, A440 (2003) (Abstract).
   Google Scholar
• Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation118, 2190–2199 (2008).
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewsli R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature263, 663–665 (1976).
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol.26, 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation106, 1477–1482 (2002).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol.40, 780–788 (2002).
   PubMed Web of Science ®Google Scholar
• Robbins IM, Christman BW, Newman JH, Matlock R, Loyd JE. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest114, 1269–1275 (1998).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: current therapy. Prog. Cardiovasc. Dis.45, 115–128 (2002).
   PubMed Web of Science ®Google Scholar
• Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet349, 1365; erratum 350, 1406 (1997).
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol.41, 2119–2125 (2003).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med.342, 1866–1870 (2000).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost in severe pulmonary hypertension. N. Engl. J. Med.347, 322–327 (2002).
   PubMed Web of Science ®Google Scholar
• Yanisagawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature332, 411–415 (1988).
   PubMed Web of Science ®Google Scholar
• Hirata Y, Katagi Y, Fukuda Y et al. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis78, 225–228 (1989).
   PubMed Web of Science ®Google Scholar
• Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir. Res.2, 90–101 (2001).
   PubMed Web of Science ®Google Scholar
• DiCarlo VS, Chen S-J, Meng QC et al. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am. J. Physiol.269, L690–L697 (1995).
   PubMedGoogle Scholar
• Benigni A, Remuzzi G. Endothelin antagonists. Lancet353, 133–138 (1999).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Badesch DB, Channick RN et al. Effect of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a one year follow- up study. Chest124, 247–254 (2003).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rich SA, Horn EM, McLaughlin VV, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest121, 1860–1868 (2002).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A et al. Sitaxsentan, an ETA receptor antagonist, for the treatment of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.169, 441–447 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest123, 989–992 (2003).
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Higenbottam TW, Dinh- Xuan AT et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet338, 1173–1174 (1991).
   PubMed Web of Science ®Google Scholar
• Hasuda T, Satoh T, Shimuchi A et al. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation101, 2066–2070 (2000).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematusu M, Oya H et al. Short-term oral administration of l-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am. J. Respir. Crit. Care Med.163, 887–891 (2001).
   PubMed Web of Science ®Google Scholar
• Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation104, 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet360, 895–900 (2002).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled nitric oxide for severe pulmonary hypertension. Ann. Intern. Med.136, 515–522 (2002).
   PubMed Web of Science ®Google Scholar
• Ghofrani A, Rose F, Schermuly et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.42, 158–164 (2003).
   PubMed Web of Science ®Google Scholar
• Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N. Engl. J. Med.343, 1342 (2000).
   PubMed Web of Science ®Google Scholar
• Schumacher YO, Zbedik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS15, 1747–1748 (2001).
   PubMed Web of Science ®Google Scholar
• Sayin T, Zenci M. Sildenafil in primary pulmonary hypertension: is there a subset of patients who respond favorably? Can. J. Cardiol.18, 676–678 (2002).
   PubMed Web of Science ®Google Scholar
• Stiebellehner L, Petkov V, Vonbank K et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest123, 1293–1295 (2003).
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation108, 2066–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol.43, 1149–1153 (2004).
   PubMed Web of Science ®Google Scholar
• Humbert M, Simonneau G. Sildenafil for pulmonary arterial hypertension: still waiting for evidence. Am. J. Respir. Crit. Care Med.169, 6–7 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts D, Lepore J, Maroo A et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest120(5), 1547–1555 (2001).
   PubMed Web of Science ®Google Scholar
• Rich S, Seiditz M, Dodin E et al. The short term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest114(3), 787–792 (1998).
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest.111, 1339–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest.108, 1141–1150 (2001).
   PubMed Web of Science ®Google Scholar
• Marcos E, Adnot S, Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med.168, 487–493 (2003).
   PubMed Web of Science ®Google Scholar
• Hauso Ø, Gustafsson BI, Loennechen JP, Stunes AK, Nordrum I, Waldum HL. Long-term serotonin effects in the rat are prevented by terguride. Regul. Pept.143(1–3), 39–46 (2007).
   PubMedGoogle Scholar
• Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov.5, 755–769 (2006).
   PubMed Web of Science ®Google Scholar
• Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the emory experience with this condition. Transplant. Proc.41(5), 1969–1971 (2009).
   PubMed Web of Science ®Google Scholar
• Chhina MK, Nargues W, Grant GM, Nathan SD. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Med.6, 19–35 (2010).
   Google Scholar
• Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am. J. Cardiol.51, 1560–1561 (1983).
   PubMed Web of Science ®Google Scholar
• Kerstein D, Levy PS, Hsu DT et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation91, 2028–2035 (1995).
   PubMed Web of Science ®Google Scholar
• Bacha EA, Hijazi ZM. Hybrid procedures in pediatric cardiac surgery. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.78–85 (2005).
   PubMedGoogle Scholar
• Prieto LR, Latson LA, Jennings C. Atrial septostomy using a butterfly stent in a patient with severe pulmonary arterial hypertension. Catheter Cardiovasc. Interv.68(4), 642–647 (2006).
   PubMed Web of Science ®Google Scholar
• Jamieson SW, Kapelanski DP, Sakakibara N et al. Pulmonary thromboendarterectomy. Experience and results in 1,500 cases. Ann. Thorac. Surg.76, 1457–1464 (2003).
   PubMed Web of Science ®Google Scholar
• Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation81, 1735–1743 (1990).
   PubMed Web of Science ®Google Scholar
• Klepetko W, Mayer E, Sandoval J et al.J. Am. Coll. Cardiol.43(12 Suppl. S), 73S–80S (2004).
   PubMed Web of Science ®Google Scholar
• Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med.345, 1465–1472 (2001).
   PubMed Web of Science ®Google Scholar
• Haddad H, Elabbssi W, Moustafa S et al. Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension. ASAIO J.51, 456–460 (2005).
   PubMed Web of Science ®Google Scholar
• Keogh AM, Mayer E, Benza RL et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J. Am. Coll. Cardiol.54(1 Suppl.), S67–S77 (2009).
   PubMed Web of Science ®Google Scholar
• International guidelines for the selection of lung transplant candidates. Joint statement of the American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am. J. Respir. Crit. Care Med.158, 335–339 (1998).
   PubMed Web of Science ®Google Scholar
• Waddell TK, Bennett L, Kennedy R, Todd TRJ, Keshavjee SH. Heart–lung or lung transplantation for Eisenmenger syndrome. J. Heart Lung Transplant.21, 731–737 (2002).
   PubMed Web of Science ®Google Scholar
• Walles T. Clinical experience with the iLA membrane ventilator pumpless extracorporeal lung-assist device. Expert Rev. Med. Devices4(3), 297–305 (2007).
   PubMed Web of Science ®Google Scholar
• Gan CT, Lankhaar JW, Marcus JT et al. Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol.290, H1528–H1533 (2006).
   PubMed Web of Science ®Google Scholar
• Tyberg JV, Taichman GC, Smith ER, Douglas NW, Smiseth OA, Keon WJ. The relationship between pericardial pressure and right atrial pressure: an intraoperative study. Circulation73, 428–432 (1986).
   PubMed Web of Science ®Google Scholar
• Ghofrani H, Barst R, Benza R et al. Future perspectives for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.54(1 Suppl. S), S108–S117 (2009).
   PubMed Web of Science ®Google Scholar
• Kwapiszewska G, Wygrecka M, Marsh LM et al. Fhl-1, a new key protein in pulmonary hypertension. Circulation108, 1183–1194 (2008).
   Google Scholar
• Campbell A, Zhao Y, Sandhu R et al. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation104, 2242–2248 (2001).
   PubMed Web of Science ®Google Scholar
• Mittal M, Roth M, Konig P et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ. Res.101, 258–267 (2007).
   PubMed Web of Science ®Google Scholar